C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

Henriksen, M.; Jahnsen, J.; Lygren, I.; Stray, N.; Sauar, J.; Vatn, M. H.; Mourn, B.
November 2008
Gut;Nov2008, Vol. 57 Issue 11, p1518
Academic Journal
Background and aims: C-reactive protein (CAP) levels are often used in the follow-up of patients with inflammatory bowel disease (IBD). The aims of this study were to establish the relationship of CRP levels to disease extent in patients with ulcerative colitis and to phenotype in patients with Crohns disease, and to investigate the predictive value of CAP levels for disease outcome. Methods: CAP was measured at diagnosis and after 1 and 5 years in patients diagnosed with IBD in southeastern Norway. After 5 years, 454 patients with ulcerative colitis and 200 with Crohns disease were alive and provided sufficient data for analysis. Results: Patients with Crohn's disease had a stronger CAP response than did those with ulcerative colitis. In patients with ulcerative colitis, CAP levels at diagnosis increased with increasing extent of disease. No differences in CAP levels at diagnosis were found between subgroups of patients with Crohns disease as defined according to the Vienna classification. In patients with ulcerative colitis with extensive colitis, CAP levels above 23 mg/I at diagnosis predicted an increased risk of surgery (odds ratio (OA) 4.8, 95% confidence interval (CI) 1.5 to 15.1, p = 0.02). In patients with ulcerative colitis, CAP levels above 10 mg/I after 1 year predicted an increased risk of surgery during the subsequent 4 years (OA 3.0, 95% Cl 1.1 to 7.8, p = 0.02). A significant association between CAP levels at diagnosis and risk of surgery was found in patients with Crohn's disease and terminal ileitis (Li), and the risk increased when CAP levels were above 53 mg/I in this subgroup (OA 6.0, 95% Cl 1.1 to 31.9, p = 0.03). Conclusions: CAP levels at diagnosis were related to the extent of disease in patients with ulcerative colitis. Phenotype had no influence on CAP levels in patients with Crohn's disease. CAP is a predictor of surgery in subgroups of patients with either ulcerative colitis or Crohn's disease.


Related Articles

  • Appendicectomy as a Therapy for Ulcerative Proctitis. Bolin, Terry Dorcen; Wong, Shing; Crouch, Roger; Engelman, Jeffrey Lionel; Riordan, Stephen Mark // American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2476 

    OBJECTIVES:Available data regarding whether appendicectomy performed after the onset of ulcerative colitis can modulate its clinical course are currently limited. This study aimed at addressing this issue.METHODS:In this study, we report a prospective case series of 30 adult patients (median age...

  • Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis. Yoon, Jin; Park, Soo; Hong, Sung; Kim, Tae; Kim, Won; Cheon, Jae // Digestive Diseases & Sciences;Apr2014, Vol. 59 Issue 4, p829 

    Background: Accurate assessment of endoscopic severity is essential to the early detection of relapses and treatment of patients with ulcerative colitis (UC). However, the relationships between non-invasive biomarkers and invasive endoscopic severity indices remain poorly understood. Methods: A...

  • Fecal Calprotectin and the Clinical Activity Index Are Both Useful to Monitor Medical Treatment in Patients with Ulcerative Colitis. Burri, Emanuel; Beglinger, Christoph; Felten, Stefanie; Lehmann, Frank // Digestive Diseases & Sciences;Feb2015, Vol. 60 Issue 2, p485 

    Background: Non-invasive monitoring of inflammatory bowel disease is an unmet clinical need as patients in clinical remission may have residual mucosal inflammation preceding clinical relapse. Aims: We aimed to assess the value of fecal calprotectin and standardized clinical activity scoring to...

  • C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Mosli, Mahmoud H; Zou, Guangyong; Garg, Sushil K; Feagan, Sean G; MacDonald, John K; Chande, Nilesh; Sandborn, William J; Feagan, Brian G // American Journal of Gastroenterology;Jun2015, Vol. 110 Issue 6, p802 

    Objectives:Persistent disease activity is associated with a poor prognosis in inflammatory bowel disease (IBD). Therefore, monitoring of patients with intent to suppress subclinical inflammation has emerged as a treatment concept. As endoscopic monitoring is invasive and resource intensive,...

  • Correlation of C-Reactive Protein with Clinical and Endoscopic Activity in Patients with Ulcerative Colitis. Karoui, Sami; Laz, Sonia; Serghini, Meriem; Bibani, Norsaf; Boubaker, Jalel; Filali, Azza // Digestive Diseases & Sciences;Jun2011, Vol. 56 Issue 6, p1801 

    Background and Aims: Evaluating disease activity is important in ulcerative colitis. Laboratory markers should be a non-invasive alternative to endoscopy for patients. The objective of our study was to scrutinize the correlation between C-reactive protein (CRP) levels and clinical and endoscopic...

  • Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Balzola, Federico; Cullen, Garret; Hoentjen, Frank; Ho, Gwo-Tzer; Russell, Richard // Inflammatory Bowel Disease Monitor;2013, Vol. 13 Issue 4, p160 

    The article discusses the medical outcomes of using infliximab to treat a steroid-dependent individuals with ulcerative colitis. It examines the failure to respond to steroids in the management of inflammatory conditions and disease-related complications. It also mentions the utilization of...

  • Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis. Jürgens, Matthias; Laubender, Rüdiger P; Hartl, Franziska; Weidinger, Maria; Seiderer, Julia; Wagner, Johanna; Wetzke, Martin; Beigel, Florian; Pfennig, Simone; Stallhofer, Johannes; Schnitzler, Fabian; Tillack, Cornelia; Lohse, Peter; Göke, Burkhard; Glas, Jürgen; Ochsenkühn, Thomas; Brand, Stephan // American Journal of Gastroenterology;Aug2010, Vol. 105 Issue 8, p1811 

    OBJECTIVES:We analyzed the efficacy and safety of the antitumor necrosis factor-α antibody infliximab (IFX) for induction therapy in patients with moderate-to-severe ulcerative colitis (UC) in a large single-center cohort.METHODS:A total of 90 UC patients treated with IFX for 14 weeks were...

  • Don't Let Inflammatory Bowel Disease Restrict Your Activities.  // Women's Health Advisor;Aug2014, Vol. 18 Issue 8, p5 

    The article discusses the types, diagnosis and treatment of inflammatory bowel disease (IBD). Topics discussed include types of IBD such as ulcerative colitis and crohn's disease, diagnosing IBD by performing a biopsy of tissue taken from digestive tract and prevention of white blood cells by...

  • Surgical aspects of inflammatory bowel diseases in pediatric and adolescent age groups. El-Asmar, Khaled; El-Shafei, Ehab; AbouZeid, Amr; El-Behery, Mosad; Abdel-Latif, Mohammed // International Journal of Colorectal Disease;Feb2016, Vol. 31 Issue 2, p301 

    Background: Inflammatory bowel disease (IBD) is increasingly encountered in children. Early disease is associated with higher complication rate with increased incidence of surgical intervention. Patients and methods: From January 2010 to June 2015, 25 patients in the pediatric and adolescent age...


Read the Article


Sign out of this library

Other Topics